DOCSLIB.ORG

Measurement of Mast Cell and Basophil Activation in Vitro As Means for Investigation of Drug Hypersensitivity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Measurement of Mast Cell and Basophil Activation in Vitro As Means for Investigation of Drug Hypersensitivity University of Southampton Faculty of Medicine Measurement of mast cell and basophil activation in vitro as means for investigation of drug hypersensitivity by Desiree Ludwig Thesis of the degree of Master of Philosophy May 2015 University of Southampton, Faculty of Medicine, Master of Philosophy, Desiree Ludwig Measurement of mast cell and basophil activation in vitro as means for investigation of drug hypersensitivity Abstract Allergic drug reactions to drugs are becoming more frequent throughout the world and are among the most common and serious form of immuno-pathological process in modern clinical medicine. These reactions can lead to life-threatening anaphylaxis which can occur within minutes of receiving the drug. Symptoms provoked by the explosive release of mediators from mast cells and basophils release may include itchiness, angioedema, difficulty breathing and circulatory collapse. There are few reliable laboratory tests available to identify those with drug hypersensitivity who may be at risk of anaphylactic shock, or even to establish if such a reaction has occurred. Confirmation of drug hypersensitivity by skin testing or oral challenge can put the patient at risk of serious reaction, and as such are expensive and performed at few centres. The aim of the study was to seek to develop new tests for drug allergy based on assessment of mast cell or basophil activation either in vitro or in vivo. Patients were recruited who were suspected of having suffered an allergic reaction to medicine and who were undergoing skin testing or oral drug challenge. Blood was collected before and following the challenge, the nature of symptoms provoked were recorded, and clinical history and demographic data obtained. The activation of basophils in vitro in response to the drug was assessed by measurement of histamine release by immunoassay or up-regulation of CD63 by flow cytometry. In parallel studies, cells of a rat basophil leukaemia cell line (RBL-703-21) that had been transfected with the α chain of the human IgE receptor, were passively sensitised with serum and challenged with the drug implicated. The release of β-hexosaminidase in cell supernatants was measured to determine the degree of drug-induced cell activation. Mast cell tryptase was successfully purified from human lung tissue, and preliminary attempts made to optimise the detection of the basophil product basogranulin by dot blotting with specific antibodies BB1 and BB5, but time did not allow measurement of either of these markers of allergic reaction in the patients studied. Skin weals were provoked in some 40% of patients following skin testing, though other symptoms were frequently recorded in the presence or even absence of a weal. These included hives, post-nasal drip, abdominal pain, vomiting, cough, shortness of breath, wheeze and stridor, and there was considerable heterogeneity in clinical responses. In patients with a positive test outcome on skin or oral challenge, raised levels of serum IgE specific to that drug were commonly observed (where the test was available). Increased expression of CD63 was provoked by in vitro challenge of basophils in a minority of patients who responded on in vivo challenge, but no histamine release into cell supernatants was detected where this was examined. Drug challenge of RBL-703-21 cells passively sensitised with patient serum resulted in the release of only a small quantities of β-hexosaminidase, and no evidence was found for direct activation of cells by the drugs themselves. There was, however, significantly higher net release of β-hexosaminidase from patients with positive skin reactions to the neuromuscular blocking agent rocuronium than in those who did not respond on skin challenge. The reliable diagnosis of drug hypersensitivity remains a formidable challenge, and there is no ready replacement of skin or oral challenge of patients with drugs suspected of causing a reaction. The present study indicates some of the difficulties as well as ways forward in developing new laboratory tests. In vitro challenge of blood basophils or passively sensitised cells of mast cell or basophil-like cell lines hold some promise, but it will be crucial for the sensitivity of such procedures to be increased and optimised with a range of drugs. Assays for mast cell or basophil products in the circulation of patients experiencing reactions should also be valuable as diagnostic tools. 1 Contents List of figures ........................................................................................................... 4 List of Tables ............................................................................................................ 6 Declaration of Authorship ....................................................................................... 8 Acknowledgment...................................................................................................... 9 List of abbreviations .............................................................................................. 10 1. Introduction ...................................................................................................... 12 1.1 Allergic drug reactions and anaphylaxis ..................................................................... 12 1.1.1 Allergy ................................................................................................................. 12 1.1.2 Adverse drug reactions and drug hypersensitivity ............................................... 17 1.1.3 Anaphylaxis ......................................................................................................... 20 1.2 Mast cells and Basophils ........................................................................................... 23 1.2.1 Mast cells ............................................................................................................ 23 1.2.2 Basophils ............................................................................................................ 29 1.3 Mediators released after basophil and mast cell activation ........................................ 33 1.3.1 Preformed mediators ........................................................................................... 33 1.3.2 Mediators that are both preformed and newly generated ..................................... 38 1.3.3 Newly generated mediators ................................................................................. 39 1.4 Identification of drug hypersensitivity ......................................................................... 41 1.4.1 In vivo and in vitro tests for drug hypersensitivity................................................. 41 1.4.2 Limitations ........................................................................................................... 43 1.3 Tryptase and histamine as markers for anaphylaxis .................................................. 46 1.5 Aims .......................................................................................................................... 47 2. Methods ............................................................................................................ 48 2.1 Subjects and sample collection ................................................................................. 48 2.2 Cell lines and cell culture conditions ......................................................................... 49 2.3 Measuring β-hexosaminidase release from passively sensitised and non-sensitised cells ...................................................................................................................... 50 2.4 Measurement of β-hexosaminidase .......................................................................... 51 2.5 Release of histamine from whole blood basophils .................................................... 51 2 2.6 PBMC isolation ......................................................................................................... 51 2.7 Basophil purification ................................................................................................. 55 2.8 Dot blotting for basogranulin ..................................................................................... 55 2.9 Basophil activation test ............................................................................................. 56 2.10 Purification of tryptase from lung............................................................................. 57 2.11 Sodium dodecyl sulfate (SDS)-PAGE ..................................................................... 59 2.12 Western blot ........................................................................................................... 59 2.13 Statistics ................................................................................................................. 60 3. Demographic features of study population ................................................... 62 4. Identification of drug hypersensitivity ........................................................... 67 4.1 Direct actions of drugs on mast cells ......................................................................... 67 4.2 Validation of the passively sensitised mast cell model ............................................... 68 4.3 Activation of passively sensitised mast cells .............................................................. 72 4.3.1 Drug induced activation ....................................................................................... 72 4.3.2 Grass pollen-induced
Load more

Recommended publications
  • Mouse and Human Fcr Effector Functions
    Pierre Bruhns Mouse and human FcR effector € Friederike Jonsson functions Authors’ addresses Summary: Mouse and human FcRs have been a major focus of Pierre Bruhns1,2, Friederike J€onsson1,2 attention not only of the scientific community, through the cloning 1Unite des Anticorps en Therapie et Pathologie, and characterization of novel receptors, and of the medical commu- Departement d’Immunologie, Institut Pasteur, Paris, nity, through the identification of polymorphisms and linkage to France. disease but also of the pharmaceutical community, through the iden- 2INSERM, U760, Paris, France. tification of FcRs as targets for therapy or engineering of Fc domains for the generation of enhanced therapeutic antibodies. The Correspondence to: availability of knockout mouse lines for every single mouse FcR, of Pierre Bruhns multiple or cell-specific—‘a la carte’—FcR knockouts and the Unite des Anticorps en Therapie et Pathologie increasing generation of hFcR transgenics enable powerful in vivo Departement d’Immunologie approaches for the study of mouse and human FcR biology. Institut Pasteur This review will present the landscape of the current FcR family, 25 rue du Docteur Roux their effector functions and the in vivo models at hand to study 75015 Paris, France them. These in vivo models were recently instrumental in re-defining Tel.: +33145688629 the properties and effector functions of FcRs that had been over- e-mail: [email protected] looked or discarded from previous analyses. A particular focus will be made on the (mis)concepts on the role of high-affinity Acknowledgements IgG receptors in vivo and on results from antibody engineering We thank our colleagues for advice: Ulrich Blank & Renato to enhance or abrogate antibody effector functions mediated by Monteiro (FacultedeMedecine Site X.
    [Show full text]
  • Basophil Activation Receptors Inhibit Mouse and Human Γ Fc
    Fcγ Receptors Inhibit Mouse and Human Basophil Activation Lydie Cassard, Friederike Jönsson, Ségolène Arnaud and Marc Daëron This information is current as of September 24, 2021. J Immunol published online 20 August 2012 http://www.jimmunol.org/content/early/2012/08/20/jimmun ol.1200968 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2012/08/20/jimmunol.120096 Material 8.DC1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 24, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published August 20, 2012, doi:10.4049/jimmunol.1200968 The Journal of Immunology Fcg Receptors Inhibit Mouse and Human Basophil Activation Lydie Cassard,*,†,1 Friederike Jo¨nsson,*,†,1 Se´gole`ne Arnaud,*,† and Marc Dae¨ron*,† Besides high-affinity IgE receptors (Fc«RI), human basophils express activating (FcgRIIA) and inhibitory (FcgRIIB) low-affinity IgG receptors. IgG receptors (FcgR) were also found on mouse basophils, but not identified.
    [Show full text]
  • Food Allergy and Food Intolerance: Specific Versus Innate Immunity Roger Davis Deutsch
    The Original Internist article Food Allergy and Food Intolerance: specific versus innate immunity Roger Davis Deutsch Nomenclature The concept of an allergy was fairly well understood when von Pirquet, an Austrian physician, first introduced the term in 1906. It was intended to denote an altered reaction to a normally innocuous substance. Two decades later allergists in Europe agreed to narrow the definition to apply only to such an altered reaction as may be characterized by an immediate onset of symptoms. Contemporary physicians recognize a distinction between immediate and delayed-type altered reactions in their nomenclature by applying the terms, “intolerance” or “sensitivity” in the case of common reactions to foods and other chemicals, where symptom onset is delayed and typically of a less acute nature than that which has come to be known as a “true” allergy, classical allergy, or Type I hypersensitivity, according to the Gell and Coombs classification system. Although both phenomena involve an aberrant immune response, the mechanisms underlying each are quite different. Broadly speaking, classical allergy is a function of the specific immune system, whilst intolerance involves activation of the innate branch of the immune system. Classical allergy is a function of the specific immune system The most prominent hallmark of specific immunity is memory; hence the rationale underlying immunization. It is termed, “specific” because it makes use of pathogen- or allergen-specific binding sites on Immunoglobulins or lymphocyte receptor molecules in the process of recognition. Prior exposure to the activating substance is therefore necessary in order to “prime” or elicit a subsequent response of the specific immune system.
    [Show full text]
  • Decreased Intracellular Histamine Concentration and Basophil Activation in Anaphylaxis
    Allergology International 69 (2020) 78e83 Contents lists available at ScienceDirect Allergology International journal homepage: http://www.elsevier.com/locate/alit Original Article Decreased intracellular histamine concentration and basophil activation in anaphylaxis Satoshi Yamaga a, Yuhki Yanase b, Kaori Ishii b, Shinichiro Ohshimo a, Nobuaki Shime a, * Michihiro Hide b, a Department of Emergency and Critical Care Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan b Department of Dermatology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan article info abstract Article history: Background: Histamine is a crucial mediator in the development of anaphylaxis. Although histamine is Received 9 February 2019 promptly degraded because of its short half-life in plasma, basophils, which release histamine, remain in Received in revised form the blood for days. To explore basophils as a potential marker and their involvement in the pathogenesis 18 May 2019 of anaphylaxis, we evaluated the intracellular histamine concentration and the degree of basophil Accepted 21 May 2019 activation in anaphylaxis patients. Available online 24 June 2019 Methods: We conducted a caseecontrol study enrolling anaphylaxis patients and healthy controls. Basophil activation was evaluated by flow cytometry using up-regulation of CD203c expression. Keywords: Anaphylaxis Results: We enrolled 23 patients and measured their blood histamine concentration. Basophil activation Basophil activation was analyzed in seven of 23 patients. The median intracellular histamine concentrations at admission CD203c were significantly lower in patients compared with controls (16.4 ng/mL [interquartile range {IQR}, 2.70 Intracellular histamine to 34.0] vs. 62.3 ng/mL [IQR, 46.0 to 85.1]; p < 0.0001).
    [Show full text]
  • Road Map for the Clinical Application of the Basophil Activation Test in Food Allergy
    Road map for the clinical application of the basophil activation test in food allergy The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Santos, A. F., and W. G. Shreffler. 2017. “Road map for the clinical application of the basophil activation test in food allergy.” Clinical and Experimental Allergy 47 (9): 1115-1124. doi:10.1111/cea.12964. http://dx.doi.org/10.1111/cea.12964. Published Version doi:10.1111/cea.12964 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34492249 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA DOI: 10.1111/cea.12964 REVIEW Road map for the clinical application of the basophil activation test in food allergy A. F. Santos1 | W. G. Shreffler2 1Department of Paediatric Allergy, King’s College London/Guy’s and St Thomas’ Summary Hospital, London, UK The diagnosis of IgE-mediated food allergy based solely on the clinical history and the 2Department of Pediatrics, Division of documentation of specific IgE to whole allergen extract or single allergens is often Allergy and Immunology, Food Allergy Center, Massachusetts General Hospital, ambiguous, requiring oral food challenges (OFCs), with the attendant risk and inconve- Harvard Medical School, Boston, MA, USA nience to the patient, to confirm the diagnosis of food allergy. This is a considerable Correspondence proportion of patients assessed in allergy clinics.
    [Show full text]
  • Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome
    cells Article Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome Heather J. Bax 1,2 , Jitesh Chauhan 1,2, Chara Stavraka 1,2,3 , Atousa Khiabany 1,2, Mano Nakamura 1, Giulia Pellizzari 1, Kristina M. Ilieva 1,4, Sara Lombardi 5, Hannah J. Gould 6,7, Christopher J. Corrigan 7,8, Stephen J. Till 7,8, Sidath Katugampola 9 , Paul S. Jones 9, Claire Barton 9,10, Anna Winship 3, Sharmistha Ghosh 3, Ana Montes 3, Debra H. Josephs 1,2,3, James F. Spicer 2,3 and Sophia N. Karagiannis 1,4,* 1 St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, London SE1 9RT, UK; [email protected] (H.J.B.); [email protected] (J.C.); [email protected] (C.S.); [email protected] (A.K.); [email protected] (M.N.); [email protected] (G.P.); [email protected] (K.M.I.); [email protected] (D.H.J.) 2 School of Cancer & Pharmaceutical Sciences, King’s College London, Guy’s Hospital, London SE1 9RT, UK; [email protected] 3 Departments of Medical Oncology and Clinical Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 9RT, UK; [email protected] (A.W.); [email protected] (S.G.); [email protected] (A.M.) 4 Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King’s College London, Guy’s Cancer Centre, London SE1 9RT, UK 5 Guy’s and St Thomas’ Oncology & Haematology Clinical Trials (OHCT), Guy’s Cancer Centre, London SE1 9RT, UK; [email protected] 6 Randall Centre for
    [Show full text]
  • Biomarkers of the Involvement of Mast Cells, Basophils and Eosinophils in Asthma and Allergic Diseases
    Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Metcalfe, D. D., R. Pawankar, S. J. Ackerman, C. Akin, F. Clayton, F. H. Falcone, G. J. Gleich, et al. 2016. “Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases.” The World Allergy Organization Journal 9 (1): 7. doi:10.1186/s40413-016-0094-3. http://dx.doi.org/10.1186/ s40413-016-0094-3. Published Version doi:10.1186/s40413-016-0094-3 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:25658402 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Metcalfe et al. World Allergy Organization Journal (2016) 9:7 DOI 10.1186/s40413-016-0094-3 REVIEW Open Access Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases Dean D. Metcalfe1*, Ruby Pawankar2, Steven J. Ackerman3, Cem Akin4, Frederic Clayton5, Franco H. Falcone6, Gerald J. Gleich7, Anne-Marie Irani8, Mats W. Johansson9, Amy D. Klion10, Kristin M. Leiferman11, Francesca Levi-Schaffer12, Gunnar Nilsson13, Yoshimichi Okayama14, Calman Prussin1, John T. Schroeder15, Lawrence B. Schwartz16, Hans-Uwe Simon17, Andrew F. Walls18 and Massimo Triggiani19 Abstract Biomarkers of disease activity have come into wide use in the study of mechanisms of human disease and in clinical medicine to both diagnose and predict disease course; as well as to monitor response to therapeutic intervention.
    [Show full text]
  • Improved Diagnosis and Therapy of Hymenoptera Venom Allergy by Component-Resolved Approaches
    Fakultät für Medizin Lehrstuhl für molekulare Allergologie Improved Diagnosis and Therapy of Hymenoptera Venom Allergy by Component-Resolved Approaches Maximilian Schiener Vollständiger Abdruck der von der Fakultät für Medizin der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) genehmigten Dissertation. Vorsitzende: Prof. Dr. Christina Zielinski Prüfende/-r der Dissertation: 1. Priv.-Doz. Dr. Simon Blank 2. Prof. Dr. Michael Sattler Die Dissertation wurde am 23.01.2018 bei der Technischen Universität München eingereicht und durch die Fakultät für Medizin am 04.07.2018 angenommen. Abstract Patients suffering from allergies due to stings of Hymenoptera like Apis mellifera, Vespula vulgaris and Polistes dominula can experience severe to fatal anaphylactic reactions. Be- sides emergency treatment, venom immunotherapy (VIT) is the only curative treatment. VIT products are available from different manufactures and treatment efficacy is very high compared to other forms of allergen-specific immunotherapy. Nevertheless, thera- peutic failures can be observed and possibly originate from different venom extraction or work-up techniques. To reduce the cost resulting from unnecessary treatment with more than one venom and to avoid the chance of de novo sensitization, the identification of the insect causing the systemic reaction has to be unambiguous. Not all patients can correctly identify the causative insect and, moreover, diagnosis by skin testing is not al- ways straightforward. Therefore, serum specific immunoglobulin E (sIgE) levels to crude insect venom can be determined in routine diagnosis. In the past, this was shown to have several disadvantages, as single allergens can be underrepresented in venom extracts due to low biologic availability or stability, thus patients sensitized to those allergens might be missed.
    [Show full text]
  • Ige in the Pathogenesis of SLE: from Pathogenic Role to Therapeutic Target
    antibodies Review IgE in the Pathogenesis of SLE: From Pathogenic Role to Therapeutic Target Yasmine Lamri 1,2 and Nicolas Charles 1,2,* 1 Centre de Recherche sur l’Inflammation, CNRS ERL8252 Faculté de Médecine Site Bichat, Université de Paris, INSERM UMR1149, 16 Rue Henri Huchard, F-75018 Paris, France; [email protected] 2 Laboratoire d’Excellence INFLAMEX, Université de Paris, F-75018 Paris, France * Correspondence: [email protected] Received: 22 October 2020; Accepted: 22 November 2020; Published: 8 December 2020 Abstract: Systemic lupus erythematosus (SLE) is a multifactorial chronic autoimmune disease, marked by the presence of autoantibodies to nuclear antigens belonging to different isotype classes. For several years, IgE antibodies have been incriminated in the development of allergic diseases and parasitic infections and different anti-IgE therapies have been developed to encounter the pathogenic role of IgE in these pathologies. Recently, multiple studies showed the presence of elevated total IgE levels and demonstrated a pathogenic role of autoreactive IgE in SLE. This review aims to summarize the findings incriminating IgE and autoreactive IgE in the pathophysiology of SLE, to describe their functional outcomes on their targeted cells as well as to discuss different IgE-related therapeutic modalities that emerged and that may be beneficial for SLE patient care. Keywords: autoantibodies; isotypes; lupus; SLE; Fc receptors; IgE; basophils; plasmacytoid dendritic cells 1. Introduction Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that predominantly affects women of childbearing age. The etiology of SLE is multifactorial and includes environmental, genetic and hormonal factors. SLE evolves by flares that can be triggered by environmental stimuli such as sun exposure or viral infections [1].
    [Show full text]
  • Basophil Activation Receptors Inhibit Mouse and Human Γ Fc
    Fcγ Receptors Inhibit Mouse and Human Basophil Activation Lydie Cassard, Friederike Jönsson, Ségolène Arnaud and Marc Daëron This information is current as of September 24, 2021. J Immunol 2012; 189:2995-3006; Prepublished online 20 August 2012; doi: 10.4049/jimmunol.1200968 http://www.jimmunol.org/content/189/6/2995 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2012/08/20/jimmunol.120096 Material 8.DC1 References This article cites 61 articles, 24 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/189/6/2995.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 24, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Fcg Receptors Inhibit Mouse and Human Basophil Activation Lydie Cassard,*,†,1 Friederike Jo¨nsson,*,†,1 Se´gole`ne Arnaud,*,† and Marc Dae¨ron*,† Besides high-affinity IgE receptors (Fc«RI), human basophils express activating (FcgRIIA) and inhibitory (FcgRIIB) low-affinity IgG receptors.
    [Show full text]
  • BASOPHIL ACTIVATION TESTING of Adults and Children Do Have a Food Allergy1
    BasophilBasophil ActivationActivation TestingTesting An in vitro test for the diagnosis of IgE and non-IgE mediated allergies Alpha Laboratories Ltd. Diagnostics 2018 A Safer Allergy Testing Alternative for Your Patients A Safer Alternative for Allergy Testing 2 A Proposed Patient Pathway for Allergy 2-3 Introducing Flow CAST® Basophil Activation Test 3 Allergy Testing- Without the Risk 4 Case Study - University Hospital Southampton Diagnosing Drug Allergy: A Rational Approach 5-6 Expert Opinion - Dr Cathy van Rooyen BÜHLMANN Allergens List 7-8 A Safer Alternative for Allergy Testing The physical symptoms of allergy can be similar BAT is a safer alternative to a provocation to those of a sensitivity or intolerance. Roughly challenge for your patient. Offering BAT before 20% of the population experience symptoms a challenge test will significantly reduce the that make them believe they have a food allergy. number of patients having to undertake a However, it is estimated that actually only 1-10% provocation challenge. For example a peanut BASOPHIL ACTIVATION TESTING of adults and children do have a food allergy1. study undertaken by Santos et al. has shown a 67% reduction in the need for oral food 3 INTRODUCTION Less than 10% of people who think they are challenge by using BAT as the primary test. allergic to penicillin are truly allergic. If someone Eliminating the need for a provocation challenge For over 40 years Alpha Laboratories is labelled as penicillin allergic they are likely to improves patient safety and comfort. be treated with broad-spectrum antibiotics2. An has been providing quality supply incorrect label of penicillin allergy may lead to The true value of BAT lies in its high specificity, and support to UK and international inappropriate use of broad-spectrum antibiotics, (reaching 100% in some studies3).
    [Show full text]
  • Innovative Approaches to Study Basophil Function in Inflammation
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Publications from Karolinska Institutet From THE DEPARTMENT OF MEDICINE Karolinska Institutet, Stockholm, Sweden INNOVATIVE APPROACHES TO STUDY BASOPHIL FUNCTION IN INFLAMMATION Zenib Aljadi Stockholm 2017 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by E-print AB 2017, Stockholm, Sweden © Zenib Aljadi, 2017 ISBN 978-91-7676-792-4 Innovative approaches to study basophil function in inflammation THESIS FOR DOCTORAL DEGREE (Ph.D.) The public defence at Karolinska Institutet will be held at Widerströmska huset, Tomtebodavägen 18A, plan 02, Karolinska Institutet, Solna th Friday, November 10 2017, 13:00 By Zenib Aljadi.MD Principal Supervisor: Opponent: Professor Joachim Lundahl Associated professor Guro Gafvelin Karolinska Institutet Karolinska Institutet Department of Medicine, Solna Department of Clinical Neuroscience Unit of Immunology and Allergy Therapeutic immune design unit Co-supervisor(s): Examination Board: Associated professor Aman Russom Professor Berndt Stegmeyer Royal Institute of Technology Umeå University School of biotechnology Department of Public Health and clinical Medicine Division of proteomics and nanobiotechnology Associated professor Sjoerd Haasl Professor Ola Winqvist Royal Institute of Technology Karolinska Institutet Department of Technology and Health Department of Medicine, Solna Center for Technology in Medicine and Health Unit of Immunology and Allergy Associated professor Nailin Li Associated professor Anna Nopp Karolinska Institutet Karolinska Institutet Department of Medicine Department of Medicine, Solna Division of Clinical Pharmacology Unit of Immunology and Allergy To my parents There are things known and there are things unknown, and in between are the doors for perception.
    [Show full text]